EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY 4.0

Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants

Jean-Yves Gillon iD, Sophie Delhomme, Delphine Launay iD, Séverine Blesson iD, Stéphanie Braillard iD, Pegah Maghdooni, Frauke Assmus, Richard Hoglund, Joel Tarning, Sabrina Loyau, Byron Arana, Mathilde Latreille-Barbier und 1 weitere

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70328 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Jean-Yves Gillon und 12 weiteren Autor:innen. Beteiligte Einrichtung: Drugs for Neglected Diseases initiative (DNDi), Chemin Camille-Vidart 15, Geneva, Switzerland. Hauptthemen laut MEDLINE: Antiprotozoal Agents, Boron Compounds. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerie van Buitenlandse Zaken, UK International Development, World Health Organization - Special Programme for Research and Training in Tropical Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

The benzoxaborole derivative DNDI‐6148 is an antiparasitic agent with activity against multiple Leishmania protozoan species, including L. infantum and L. donovani , which cause visceral leishmaniasis. We investigated the safety, tolerability and pharmacokinetics of single oral doses of DNDI‐6148 in a randomized, parallel‐group, placebo‐controlled, first‐in‐human study in 64 healthy participants.

Methods

Eight cohorts of eight participants each were enrolled. DNDI‐6148, formulated as a suspension in ORA‐Sweet® was administered orally as single 10–380 mg doses. Pharmacokinetics (PK) and safety were assessed for four (cohorts receiving 10–80 mg DNDI‐6148) or six (cohorts receiving 160–380 mg DNDI‐6148) days after dosing.

Results

Sixteen adverse events (AEs) were experienced by 13 participants (20.3%), all mild or moderate in severity and resolved by the end of the study. No AE led to any participant withdrawal, and no fatal or serious AEs were reported. DNDI‐6148 was relatively slowly absorbed (t max ranging between 3 and 12 h) under fasting conditions, with increase in plasma concentrations modestly sub‐proportional to dose. The mean half‐life was between 12.80 and 25.42 h. The fraction of the dose excreted by the kidneys as unchanged DNDI‐6148 was below 0.2%. Trace amounts of three metabolites (formed by oxidation, deboronation, dehydrogenation of DNDI‐6148) were detected in plasma.

Conclusion

After a single administration of up to 380 mg by oral route, DNDI‐6148 had an acceptable safety and tolerability profile and a favourable PK profile. These data support further clinical development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiprotozoal AgentsBoron CompoundsHumansAdultMaleFemaleMiddle AgedYoung AdultAdministration, OralHealthy VolunteersDose-Response Relationship, DrugAdolescentArea Under CurveDouble-Blind MethodHalf-LifeBenzoxazolesPyridines

Stichwörter der Autor:innen

first‐in‐humanleishmaniasisnew chemical entitypharmacokineticssafety

Substanzen

Antiprotozoal AgentsBoron CompoundsDNDI-6148BenzoxazolesPyridines

Autor:innen und Institutionen

  • Drugs for Neglected Diseases initiative (DNDi), Chemin Camille-Vidart 15, Geneva, Switzerland.
  • SGS Belgium SA, Vieux Chemin du Poète, 10, Wavre, Belgium.
  • Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand and Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, Universit…
  • PhinC Development, 36, rue Victor Basch, Massy, France.
  • Eurofins Optimed SAS, 1, rue des Essarts, Gières, France.

ORCID-Profile: Jean-Yves Gillon, Delphine Launay, Séverine Blesson, Stéphanie Braillard, Yves Donazzolo

Förderung

  • Ministerie van Buitenlandse Zaken
  • UK International Development
  • World Health Organization - Special Programme for Research and Training in Tropical Diseases
  • Médecins sans Frontières International
  • other private foundations and individuals
  • Bundesministerium für Bildung und Forschung
  • Direktion für Entwicklung und Zusammenarbeit
  • Gates Foundation

Zitieren

APA

Gillon, J. Y., Delhomme, S., Launay, D., Blesson, S., Braillard, S., Maghdooni, P., Assmus, F., Hoglund, R., Tarning, J., Loyau, S., Arana, B., Latreille-Barbier, M., & Donazzolo, Y. (2026). Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70328

Vancouver

Gillon JY, Delhomme S, Launay D, Blesson S, Braillard S, Maghdooni P, et al. Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70328

BibTeX
@article{Gillon2026,
  author = {Gillon, Jean-Yves and Delhomme, Sophie and Launay, Delphine and Blesson, Séverine and Braillard, Stéphanie and Maghdooni, Pegah and Assmus, Frauke and Hoglund, Richard and Tarning, Joel and Loyau, Sabrina and Arana, Byron and Latreille-Barbier, Mathilde and Donazzolo, Yves},
  title = {Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70328}
}
Kostenlos starten →